Synthesis and identification of GZD856 as an orally bioavailable Bcr-AblT315I inhibitor overcoming acquired imatinib resistance

• 主要な著者: Xiaoyun Lu (著者), Zhang Zhang (著者), Xiaomei Ren (著者), Deping Wang (著者), Ke Ding (著者)
• フォーマット: 図書
• 出版事項: Taylor & Francis Group, 2017-01-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Bcr-AblT315I induced drug resistance remains a major challenge to chronic myelogenous leukemia (CML) treatment. Herein, we reported GZD856 as a novel orally bioavailable Bcr-AblT315I inhibitor, which strongly suppressed the kinase activities of both native Bcr-Abl and the T315I mutant with IC50 valu...